Yale School of Medicine

Dermatology, Yale School of Medicine

Dermatology, Yale School of Medicine

Dermatology
PO Box 208030
New Haven, CT 06520-8030

Current Clinical Trials

Transimmunization was developed after years of laboratory research advanced the understanding of the underlying principles of ECP (Extracorporeal photochemotherapy or photopheresis).  The scientific basis of ECP is the ability to stimulate the development of powerful stimulators of the immune system called dendritic cells.  Transimmunization is a more efficient means by which to bring these dendritic cells in contact with target cancer cells, before they are retuned to the body to stimulate an anti-tumor immune response.

A clinical trial of Transimmunization for the treatment of solid cell tumors in stage IIIB or greater non-small cell lung cancer (NSCLC) is currently underway at Yale.  Information about this trial is listed below.

HIC Number 26573

Full Title

Phase I Feasibility Study: Combined Modality Treatment with Transimmunization for Non-Small Cell Lung Cancer

Trial Type

Therapeutic

Disease

Phase I

PI

Lynn Wilson

Primary Objective

To assess the safety of utilizing Transimmunization as a component of combined modality treatment of stage IIIB or greater non-small cell lung cancer (NSCLC).

Target Population

Histologically confirmed non-small cell lung cancer; Staging by CT scan of chest, abdomen and MRI of brain; Willing and able to undergo two lung biopsy procedures by bronchoscopy.

Exclusion

History of, or active infection with, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; History of allergic reactions attributed to compounds of similar composition to 8 methoxypsoralen.

FDA Phase

I


For further information on this clinical trial, please call the Yale Cancer Center Clinical Trials Office at 203-785-5702.